There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Citius Pharmaceuticals (CTXR – Research Report) and Aprea Therapeutics (APRE – Research Report) with bullish sentiments.
Citius Pharmaceuticals (CTXR)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Citius Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Thursday at $0.97.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
Currently, the analyst consensus on Citius Pharmaceuticals is a Moderate Buy with an average price target of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
Aprea Therapeutics (APRE)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aprea Therapeutics today and set a price target of $20.00. The company’s shares closed last Thursday at $4.00, close to its 52-week low of $2.78.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Aprea Therapeutics is a Moderate Buy with an average price target of $20.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CTXR:
- Citius Pharma (CTXR) Q3 Earnings Cheat Sheet
- Citius Pharmaceuticals price target lowered to $4 from $6 at H.C. Wainwright
- Citius Pharmaceuticals receives Complete Response Letter from FDA for LYMPHIR
- Citius Pharmaceuticals to be added to Russell 3000, Russell 2000 Indexes
- Citius Pharmaceuticals reports ‘positive’ results from Phase 2B Halo-Lido study
